The FDA’s Growing Crisis of Accountability as Hundreds of Postmarket Drug Studies Face Indefinite Delays

When the Food and Drug Administration (FDA) grants approval to a new pharmaceutical product, it is rarely the end of the scientific inquiry. Recognizing that pre-approval clinical trials often involve limited patient populations and truncated timeframes, the agency frequently authorizes drugs and medical devices with a "postmarket" mandate: manufacturers must continue to conduct rigorous safety and efficacy studies after the product hits the shelves. However, a systemic breakdown in this follow-through process has emerged, with hundreds of these required studies languishing in a state of indefinite delay, leaving patients and physicians to navigate the risks of treatments with incomplete evidence.

The case of the autoimmune drug Tavneos serves as a stark illustration of this regulatory friction. When the FDA evaluated Tavneos several years ago for the treatment of rare, life-threatening vasculitis, agency experts expressed significant skepticism, citing "limited safety data." The agency ultimately approved the drug in 2021, but with a critical caveat: the manufacturer was required to launch a multi-year postmarket study to verify the drug’s long-term safety profile. Today, that study is years behind schedule. According to federal databases, as of last fall, only 21 of the targeted 300 patients had been enrolled. Meanwhile, the FDA has flagged dozens of cases of potential liver damage associated with the medication—a direct safety concern that the delayed study was specifically designed to investigate.

A Pattern of Regulatory Inertia

The issues surrounding Tavneos are not an anomaly. An exhaustive analysis of FDA data by KFF Health News reveals a troubling trend: nearly 600 postmarket studies are currently listed as behind schedule. This backlog involves roughly 350 different products, ranging from specialized medical devices to biologics and vaccines. In many instances, the research is not merely lagging; it has been stalled for over a decade, with some manufacturers still in the preliminary stages of drafting study protocols years after their products entered the market.

The implications for public health are profound. When studies are delayed, the medical community remains in a "fog of uncertainty" regarding the true benefit-risk ratio of a treatment. Cardiologist Dr. Sanket Dhruva, an associate professor at the University of California-San Francisco, notes that these requirements have "often proven toothless." For patients suffering from chronic or terminal illnesses, this lack of follow-through means they may be staking their health and their financial resources on products that have yet to be proven as effective or safe as their marketing claims suggest.

Chronology of Failure: From Approval to Oversight

The regulatory lifecycle for these products often follows a predictable, yet concerning, pattern. Initially, the FDA uses "accelerated approval" or similar expedited pathways to bring drugs to patients with few treatment options. While this speeds access, it places the burden of proof on the postmarket phase.

For instance, the CustomFlex Artificial Iris, intended for patients with severe ocular defects, was approved in 2019 with a mandate for a five-year study. Years later, enrollment remains at zero. Similarly, the Scandinavian Total Ankle Replacement system, which has been under the spotlight since 2009, failed to meet its recruitment targets, with reports indicating that nearly half of the patients enrolled in the partial study experienced adverse events, including the need for surgical revisions or device removal.

The opioid painkiller Oxaydo, approved in 2011 with the promise of abuse-deterrence, faced a "failure to respond" letter from the FDA in 2022. By the time the agency sought to hold the manufacturer accountable, the product had changed hands multiple times, and the manufacturer eventually discontinued the drug, effectively rendering the safety study moot and leaving the original questions regarding its addiction risks unanswered.

Financial and Ethical Implications

The economic burden of these delays is massive. A 2022 report from the HHS Office of Inspector General estimated that Medicare and Medicaid spent over $18 billion between 2018 and 2021 on drugs that had received accelerated approval but failed to complete their confirmatory trials on time. When manufacturers profit from these drugs while failing to fulfill their research obligations, they are essentially rewarded for maintaining a status quo of incomplete information.

Furthermore, the recent shift in FDA policy, which aims to make a single clinical trial the "default requirement" for new drug approvals rather than the traditional two, is expected to place even greater strain on the post-approval system. Dr. Aaron Kesselheim, a professor at Harvard Medical School, warns that reducing pre-approval rigor "will inevitably put a lot of pressure on the post-approval system." While FDA officials argue that this policy will reduce costs and speed up delivery to patients, critics argue that it fundamentally shifts the risk from the manufacturer to the patient.

The Case of Tavneos: A Regulatory Standoff

The conflict over Tavneos has reached a boiling point. The FDA is currently attempting to withdraw the drug’s approval, alleging that the original clinical trial data was "manipulated" by the manufacturer, ChemoCentryx—a company since acquired by Amgen. The FDA’s April 2026 communication to Amgen stated that the agency "can no longer conclude that there is, or has ever been, a valid demonstration of substantial evidence of effectiveness."

Amgen continues to contest these allegations, asserting that the drug’s benefits outweigh the risks and that the data remains valid. The company also pointed to the inherent difficulty of recruiting for studies when patients are already being treated with the drug, claiming that many are unwilling to participate in a study that might involve a placebo. This defense highlights a recurring theme in the industry: the difficulty of executing randomized controlled trials after a product is already widely available on the market.

However, the international community has taken a more decisive stance. The European Union recently revoked the marketing authorization for Tavneos, citing similar concerns regarding efficacy and safety. The U.S. remains locked in a battle to pull the drug, representing one of the few instances where the FDA is actively attempting to reverse a previous approval based on the failure of the manufacturer to provide robust, post-approval validation.

Official Responses and the Path Forward

The Department of Health and Human Services (HHS), which oversees the FDA, maintains that not all delays are evidence of product failure. HHS spokesperson Emily Hilliard stated that assessing the significance of a delay requires a "case-specific review" and that delays can occur for legitimate reasons, such as recruitment challenges or evolving scientific protocols. "The fact that a study is delayed should not be treated as evidence that a product has an unresolved safety or effectiveness issue," Hilliard noted.

Despite these assurances, the sheer volume of delayed studies suggests a systemic weakness in enforcement. The FDA possesses the legal authority to impose strict penalties or revoke approvals for companies that fail to conduct mandated research, yet these powers are exercised sparingly.

Broader Impact on Public Health

The erosion of the postmarket study system threatens the integrity of the entire pharmaceutical approval pipeline. When doctors and patients lose faith in the evidence underpinning medical treatments, the standard of care becomes fractured. The reliance on post-approval studies was designed to be a safety net, protecting the public from the limitations of initial clinical trials. When that net is full of holes, the consequences are felt in the form of preventable side effects, wasted healthcare dollars, and a diminished trust in the regulatory process.

Moving forward, the medical community and policy advocates are calling for greater transparency in the FDA’s database tracking. They suggest that the agency should implement more aggressive timelines, automatic penalties for missed milestones, and clearer consequences for companies that fail to demonstrate the clinical benefits of their products. As the FDA continues to push for faster drug approvals, the debate over how to balance speed with safety will remain the defining challenge of the agency’s mission. Without a meaningful commitment to enforcing postmarket accountability, the promise of innovation may continue to be overshadowed by the reality of unresolved risks.